SlideShare ist ein Scribd-Unternehmen logo
1 von 68
Downloaden Sie, um offline zu lesen
Dilated cardiomyopathy
Dr. Avinash D. Arke
MD FNB
Introduction
• Definition:
– Dilated left ventricle with systolic dysfunction
– not caused by Ischaemic or valvular heart disease
– Cardiac dilatation with systolic dysfunction
Learning objectives
• Epidemiology
• Etiology
• Pathology
• Genetics
• Clinical features
• Natural history
• Diagnosis
• Management
IDIOPATHIC DILATED CARDIOMYPATHY
EPIDEMIOLOGY
• ANNUAL INCIDENCE 5-8/100,000
• PREVELANCE 36/ 100,000
• INCREASED RISK ASSOCIATED WITH:
– MALE GENDER
– BLACK RACE
– HYPERTENSION
– CHRONIC BETA-AGONIST USE
Dilated cardiomyopathy
Causes
Dilated cardiomyopathy
Causes
• Ischemic: = 50% atherosclerosis, Kawasaki
disease, anomalous origin of left coronary artery
• Idiopathic = 45%
• Hereditary: = 25 – 35% autosomal dominant,
autosomal recessive, X-linked,
mitochondrial
• Acute and chronic myocarditis: coxsackievirus,
HIV adenovirus,
• Autoimmune diseases
• Chronic tachycardia
• Drugs: alcohol, sympathomimetics, anthracyclines
• End-stage hypertrophic cardiomyopathy
• Endocrine: growth hormone deficiency, hyperthyroidism,
hypothyroidism, hypocalcemia,
diabetes mellitus, pheochromocytoma
• Inborn errors of metabolism
• Muscular dystrophies
• Nutritional deficiency: selenium, carnitine, thiamine
• Peripartum
• Structural heart disease
• Systemic hypertension
• Toxins: cobalt, lead
Pathology
• Cardiac dilatation
– ? Adaptive – due to increased loading conditions
– Idiopathic DCM – maladaptive..
• Myocellular hypertrophy and cell death
– Cardiac hypertrophy – adaptive response
increase in collagen content
preserves myocardial performance
– Cumulative loss of myofibrils and cardiac
myocytes
apoptosis, cellular necrosis
decrease in the wall thickness
• Extracellular matrix remodeling
– Cardiac fibroblast proliferate
– Mechanically stable cross linked collagen is
degraded by metalloproteinases
– Excess of poorly cross-linked collagen is deposited
into interstitium
– Increase myocardial mass, intersitial fibrosis,
ventricular dilatation
IDIOPATHIC DILATED CARDIOMYOPATHY
PATHOLOGIC FINDINGS
GENETICS
Sarcomere Cytoskeleton
Sarcolemma Nucleus
Dilated cardiomyopathy
MOLECULAR DEFECTS IN DILATED
CARDIOMYOPATHY
Fatkin D, et al. NEJM 1999;341
GENES
Lamin A/C
δ-sarcoglycan
Dystrophin
Desmin
Vinculin
Titin
Troponin-T
α-tropomyosin
ß-myosin heavy chain
Actin
Mitochondrial DNA mutations
Dilated cardiomyopathy
Dilated cardiomyopathy
FAMILIAL DILATED CARDIOMYOPATHY
COMMON ASSOCIATED ABNORMALITIES
• Conduction system disease
• Skeletal muscle myopathy or muscular
dystrophy
• autosomal dominant inheritance pattern is
most common
• Recessive , X-linked, mitochondrial
• Extracardiac manifestations:
– Sensorineural hearing loss
– Neutropenia
HISTOPATHOLOGY OF ACUTE
LYMPHOCYTIC MYOCARDITIS
INCIDENCE OF BIOPSY-PROVEN MYOCARDITIS IN
PATIENTS WITH DILATED CARDIOMYOPATHY
Series Year Patients Positive Biopsy
Kunkel et al 1978 66 6%
Mason et al 1980 400 3%
Noda 1980 52 0.5%
Baandrup et al 1981 132 1%
O’Connell et al 1981 68 7%
Nippoldt et al 1982 170 5%
Fenoglio et al 1983 135 25%
Unverferth et al 1983 59 6%
Parillo et al 1984 74 26%
Zee-Cheng et al 1984 35 63%
Daly et al 1984 69 17%
Bolte et al 1984 91 20%
Hosenpud et al 1985 38 16%
Mason et al 1995 2233 10%
McCarthy et al 1997 1757 14%
TOTAL 5379 11.5%
Clinical features
• Heart failure
– congestion : edema, orthopnea, paroxysmal
nocturnal dyspnea
– reduced cardiac output : fatigue, dyspnea on
exertion
• Arrhythmias and/or conduction system
disease
• Thromboembolic disease (from left ventricular
mural thrombus)- stroke
• Heart failure symptoms 75%-85%
• Anginal chest pain 8%-20%
• Emboli (systemic or pulmonary) 1%-4%
• Syncope <1%
• Sudden cardiac death <1%
Diagnosis
• ECG
• CXR
• 2 D - Echo
DILATED CARDIOMYOPATHY
ELECTROCARDIOGRAPHIC FINDINGS
Disease Etiology Pathologic Q-waves
Ischemic cardiomyopathy 10/12 (83%)*
(n=15)
Idiopathic cardiomyopathy 2/21 (10%)+ #
(n=21)
*LBBB (n=2); paced rhythm (n=1)
+ LVH (n=10); IVCD (n=3)
# P < 0.003
Feld H, et al. Am J Med 1993;94:547-8
Dilated cardiomyopathy
Dilated cardiomyopathy
Dilated cardiomyopathy
Dilated cardiomyopathy
Dilated cardiomyopathy
SEGMENTAL WALL MOTION ABNORMALITIES
IN DILATED CARDIOMYOPATHY
• Regional wall motion abnormalities observed in at least
50% of patients with non-ischemic causes of dilated
cardiomyopathy
• Most frequent wall motion abnormalities:
– anterior wall & apex
• Posterior and lateral walls most likely to be preserved
• Type of abnormality:
– hypokinesis (83%)
– akinesis (11%)
– dyskinesis (6%)
• Heterogeneity in regional oxidative metabolism using C-
11 acetate clearance has been demonstrated in DCM
AJC 1990;65:364-70; Arch Int Med 1992;152:769-72; JACC 1995;25:1258-62
MRI
• black blood images: enlarged cardiac chambers
and thin myocardial walls
• Cine images: show LV hypokinesia, increased
volumes, (end-diastolic volumes that constitute a
dilated CMP: > 140 mL for the LV and > 150 mL
for the RV
• Phase-contrast sequences: impaired diastolic
function. transvalvular flow may be characterized
by a restrictive pattern
• Late gadolinium-enhancement
Non ischaemic DCM
Ischemic DCM
Dilated cardiomyopathy
Dilated cardiomyopathy
Differentiation of ischaemic from non-ischaemic DCM
ACC/AHA HEART FAILURE EVALUATION GUIDELINES
CLASS I & II RECOMMENDATIONS
• Laboratory Studies
– Blood count, urinalysis, electrolytes, renal function,
glucose, LFTs (class I; level C)
– Thyroid stimulating hormone (class I; level C)
– Fe/TIBC, ferritin (class IIa, level C)
– Urinary screening for hemochromatosis (class IIa; level C)
– Measurement of ANA, rheumatoid factor, urinary VMA and
metanepherines in selected patients (class IIa; level C)
– HIV testing (class IIb; level C)
• Electrocardiogram (class I; level C)
• Chest x-ray (class I; level C)
• Echocardiogram/Doppler or radioventriculogram (class I;level
C)
-Adapted from Hunt SA et al. Circulation 2001;104:2996-3007
Genetic test
• Genetic Cardiomyopathy dilated panel Next Generation Sequencing Panel:
• ABCC9, ACTC1, ACTN2, BAG3, CSRP3, DES, DMD, DSG2, EYA4, FKTN, GATAD1, LAMP2, LDB3,
LMNA, MYBPC3, MYH6, MYH7, NEXN, PLN, PSEN1, MT-ND1, MT-ND5, MT-ND6, MT-TD,
MT-TH, MT-TI, MT-TK, MT-TL1, MT-TL2, MT-TM, MT-TQ, MT-TS1, MT-TS2, PSEN2, RBM20,
SCN5A, SDHA, SGCD, TAZ, TCAP, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL DNA
Test
Dilated cardiomyopathy
IDIOPATHIC DILATED CARDIOMYOPATHY
NATURAL HISTORY
Dec GW, Fuster V. NEJM 1994;331:1564-75
Transplant free survival in acute DCM
SPONTANEOUS IMPROVEMENT IN ACUTE
DILATED CARDIOMYOPATHY
UNIVARIATE PREDICTORS OF IMPROVEMENT
short duration of symptoms
higher cardiac output
lower NYHA functional classification
smaller LV end-diastolic dimension
lower filling pressures
higher serum sodium concentration
STEPWISE REGRESSION MODEL
short duration of symptoms
higher serum sodium concentration
lower right atrial pressure
lower pulmonary capillary wedge pressure
-Steimle AE, et al. JACC 1994;23:553-9
CHANGE IN LVEF BY LVEDD: IMAC Trial
0.32
0.56
0.22
0.26
0.39
0.12
0.20
0.29
0.09
0
0.2
0.4
0.6
Baseline
LVEF
6 months
LVEF
12 months
LVEF
< or = 6.0
>6 to 7.0
> 7.0
LVEDD (cm)
LVEF
McNamara D, et al.
AHA, 2001
N=82
IDCM:PROGNOSTIC FEATURES
• VENTRICULOGRAPHIC FINDINGS
– Degree of impairment in LVEF
– Extent of left ventricular enlargement
– Coexistent right ventricular dysfunction
– Ventricular mass/volume ratio
– Global wall motion abnormalities
– Left ventricular sphericity
• CLINICAL FINDINGS
– Favorable prognosis: NYHA < IV, younger age, female
sex
– Poor prognosis: Syncope, persistent S3 gallop, right-
sided heart failure, AV or bundle branch block,
hyponatremia, troponin elevation, increased BNP,
maximum oxygen uptake < 12 ml/kg/min
OUTCOME IN IDIOPATHIC DILATED CARDIOMYOPATHY
PREDICTIVE VALUE OF TROPONIN T
Months
Event-FreeRate(%)
Sato Y et al. Circulation 2001;103:372
Grp 1: TnT < 0.02
ng/mL during follow-
up period
Grp 2: TnT > 0.02
ng/mL initially but
fell to < 0.02 ng/mL
during follow-up
Grp 3: TnT > 0.02
ng/mL throughout
follow-up period
N=33
N=10
N=17
MYOCARDIAL CONTRACTILE RESERVE PREDICTS
IMPROVEMENT IN DILATED CARDIOMYOPATHY
Naqvi TS et al. J Am Coll Cardiol 1999;34:1537-44
Dilated cardiomyopathy
668N =
Fas gene expression
HighModerateLow
ChangeinEFat12months(%)
50.0
40.0
30.0
20.0
10.0
0.0
-10.0
-20.0
668N =
Fas gene expression
HighModerateLow
40.0
30.0
20.0
10.0
0.0
-10.0
Fas Expression and LV Recovery
p=0.002 p=0.006
Six months Twelve months
Sheppard, AHA 2003
IMAC TRIAL RESULT:APOPTOSIS AND RECOVERY OF VENTRICULAR
FUNCTION
Expression of TNF-alpha and FasL did not predict the recovery
Sheppard, AHA 2003
TNFR1 Expression and LV Recovery
Six months Twelve months
NONINVASIVE ASSESSMENT OF CORONARY ARTERY
DISEASE IN NEW ONSET DILATED CARDIOMYOPATHY
• Retrospective studies have shown up to 94% of patients
with idiopathic dilated cardiomyopathy will have
myocardial perfusion defects
– Reversible defect(s): 60%
– Fixed defect(s): 15%
– Reversible+ fixed defect(s): 25%
• Global myocardial blood flow reserve (dipyridamole-
induced) is diminished in DCM patients compared to
controls using PET imaging
• Low myocardial blood flow reserve correlates with high
left ventricular wall stress and anaerobic metabolism
Ann Inter Med 1992;152:679-72; JACC 2000;35:19-28.
INDICATIONS FOR CORONARY ANGIOGRAPHY IN NEW
ONSET CARDIOMYOPATHY
ACC/AHA CONSENSUS GUIDELINES (2001)
• Patients with Known Coronary Artery Disease/Angina Pectoris
– Revascularization recommended in vast majority of such individuals
with multivessel disease. Little role for non-invasive testing.
– Coronary angiography considered Class I Recommendation (Level of
evidence: B)
• Patients with Known Coronary Artery Disease Who Lack Angina
– No controlled trials have examined whether coronary revascularization
can improve outcomes in this population
– Many centers first evaluate patient for myocardial hibernation
– Coronary angiography considered Class IIa Recommendation (Level of
Evidence:C)
• Patients with or without Chest Pain in Whom Coronary Artery
Disease has Not Been Evaluated
– Approximately 35% of patients with IDCM will report angina-like pain
– Coronary angiography should be considered Class IIa
recommendation (Level of Evidence: C)
Hunt SA,et al. Circulation 2001;104:2996
RIGHT
VENTRICULAR
BIOPSY
TECHNIQUE
ENDOMYOCARDIAL BIOPSY IN DILATED CARDIOMYOPATHY
INDICATIONS FOR ENDOMYOCARDIAL
BIOPSY
• Acute dilated cardiomyopathy with refractory heart failure
symptoms
• Rapidly progressive ventricular dysfunction in an
unexplained cardiomyopathy of recent onset
• New onset cardiomyopathy with recurrent ventricular
tachycardia or high grade heart block
• Heart failure in the setting of fever, rash, and peripheral
eosinophilia
• Dilated cardiomyopathy in setting of systemic diseases
known to affect the myocardium (systemic lupus erythematosus,
polymyositis, sarcoidosis)
Wu LA, et al. Mayo Clin Proc 2001;76:1030-8
DILATED CARDIOMYOPATHY
PROVEN THERAPEUTIC OPTIONS
TREATMENT INDICATIONS
ACE Inhibitors Symptomatic heart failure and
asymptomatic LV dysfunction
ARBs ACE intolerance
Hydralazine- nitrates ACE intolerance
Diuretics Volume overload
Potassium/Magnesium Diuretic-induced depletion
Beta-blockers Symptomatic heart failure in addition to
ACE inhibitor
Digoxin Persistent heart failure despite
diuretics, ACE inhibitor
Warfarin Chronic or paroxysmal atrial fibrillation
LV thrombus or prior embolic event
ICD Cardiac arrest; uncontrolled VT
Dilated cardiomyopathy
Recommendations for ICD in DCM
Recommendations for CRT in DCM
Role of CRT
• Survival estimates at 4 years were 55% for ICM and 77% for
DCM groups (P<.001), respectively, whereas no significant
difference in the incidence of appropriate/inappropriate
ICD shocks was observed
• Conclusion: In response to CRT and in contrast to ICM,
DCM patients experienced greater improvement in left
ventricular systolic function and reverse remodeling while
also sustaining a greater survival benefit.
• Differential outcome of cardiac resynchronization therapy in ischemic
cardiomyopathy and idiopathic dilated cardiomyopathy
Christopher J et al, Heart rhythm, March 2011 Volume 8, Issue 3, Pages 377–382.
et al
Dilated cardiomyopathy
DCM with atrial fibrillation
Rate control Rhythm control
Alcoholic cardiomypathy
• Diagnosis of exclusion
• 3.8 – 43 % cases with IDCM
• Ethanol consumption > 80 gm/day for male
and > 40 gm/ day for female for a period of > 5
years
• Absteinance from alcohol after the diagnosis
may improve the LVEF.
Peripartum cardiomyopathy
• definition --- four criteria: three clinical and one echocardiographic –
1. Development of heart failure during last trimester of pregnancy or first
six months post partum.
2. Absence of any identifiable cause for cardiac failure.
3. Absence of any recognizable heart disease prior to last trimester of
pregnancy.
4. Echocardiographic criteria- Demonstrable echocardiographic proof of left
ventricular systolic dysfunction. Ejection fraction less than 45%, left
ventricular fractional shortening less than 30% or left ventricular end-
diastolic dimension >2.7cm/m square of body surface area.
Novel surgical options
• Mitral valve repair
• Surgical ventricular reconstruction
• Surgical attempts to regenerate lost or
damaged myocardium with transplanted stem
cells.
Dilated cardiomyopathy
• In refrctory cases –
• LVAD
• Heart transplatation
Summary
• DCM – important cause of morbidity and
mortality
• Ischaemic CMP and Familial DCM – major causes
of DCM: role of CAG and genetic counselling
• Advancement in immunoabsorption and
immunosuppression therapy for myocarditis has
improved the survival in recent years.
• further studies are needed to fill the lacuna in our
knowledge about DCM
Thank you !

Weitere ähnliche Inhalte

Was ist angesagt? (20)

EISENMENGER SYNDROME- PAUL WOOD
EISENMENGER SYNDROME- PAUL WOODEISENMENGER SYNDROME- PAUL WOOD
EISENMENGER SYNDROME- PAUL WOOD
 
HOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathyHOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathy
 
Sinus of valsalva aneurysm
Sinus of valsalva aneurysmSinus of valsalva aneurysm
Sinus of valsalva aneurysm
 
ECG Changes in Myocardial Infarction
ECG Changes in Myocardial InfarctionECG Changes in Myocardial Infarction
ECG Changes in Myocardial Infarction
 
SVT
SVTSVT
SVT
 
Mitral valve prolapse
Mitral valve prolapseMitral valve prolapse
Mitral valve prolapse
 
Takotsubo Cardiomyopathy
Takotsubo CardiomyopathyTakotsubo Cardiomyopathy
Takotsubo Cardiomyopathy
 
Ecg changes in mi
Ecg changes in miEcg changes in mi
Ecg changes in mi
 
Restrictive cardiomyopathy
Restrictive cardiomyopathyRestrictive cardiomyopathy
Restrictive cardiomyopathy
 
EBSTEIN ANOMALY
EBSTEIN ANOMALYEBSTEIN ANOMALY
EBSTEIN ANOMALY
 
Echo Mitral Stenosis
Echo Mitral StenosisEcho Mitral Stenosis
Echo Mitral Stenosis
 
Myocardial infarction (MI) ecg localisation
Myocardial infarction (MI) ecg localisationMyocardial infarction (MI) ecg localisation
Myocardial infarction (MI) ecg localisation
 
Echo assessment of cardiomyopathy pdf
Echo assessment of cardiomyopathy pdfEcho assessment of cardiomyopathy pdf
Echo assessment of cardiomyopathy pdf
 
Bundle branch blocks
Bundle branch blocksBundle branch blocks
Bundle branch blocks
 
LBBB
LBBBLBBB
LBBB
 
Brugada syndrome
Brugada syndromeBrugada syndrome
Brugada syndrome
 
Dynamic auscultation
Dynamic auscultationDynamic auscultation
Dynamic auscultation
 
Aortic regurgitation
Aortic regurgitationAortic regurgitation
Aortic regurgitation
 
electrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASESelectrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASES
 
Constrictive pericarditis
Constrictive pericarditisConstrictive pericarditis
Constrictive pericarditis
 

Andere mochten auch

Andere mochten auch (11)

Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
Cardiac tamponade
Cardiac tamponade Cardiac tamponade
Cardiac tamponade
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Cardiac tamponade
Cardiac tamponadeCardiac tamponade
Cardiac tamponade
 
Pericardial effusion
Pericardial effusionPericardial effusion
Pericardial effusion
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
cardiomyopathy
cardiomyopathycardiomyopathy
cardiomyopathy
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Tachyarrhtymia induced cardiomyopathy
Tachyarrhtymia induced cardiomyopathyTachyarrhtymia induced cardiomyopathy
Tachyarrhtymia induced cardiomyopathy
 

Ähnlich wie Dilated cardiomyopathy

MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER Praveen Nagula
 
Cardiac Amyloidosis Final Presentation.pdf
Cardiac Amyloidosis Final Presentation.pdfCardiac Amyloidosis Final Presentation.pdf
Cardiac Amyloidosis Final Presentation.pdfJonathanStrandberg1
 
Multiple myeloma and al amyloidosis
Multiple myeloma and al amyloidosisMultiple myeloma and al amyloidosis
Multiple myeloma and al amyloidosisdrucsamal
 
cardiomyopathy.ppt
cardiomyopathy.pptcardiomyopathy.ppt
cardiomyopathy.pptJeenaRaj10
 
cardiomyopathy2 (3).ppt
cardiomyopathy2 (3).pptcardiomyopathy2 (3).ppt
cardiomyopathy2 (3).pptJeenaRaj10
 
Cardiogenic shock and IABP.pptx
Cardiogenic shock and IABP.pptxCardiogenic shock and IABP.pptx
Cardiogenic shock and IABP.pptxPRIYANKA BHATI
 
Coronary Artery Aneurysms and Ectasia
Coronary Artery Aneurysms and Ectasia Coronary Artery Aneurysms and Ectasia
Coronary Artery Aneurysms and Ectasia Michael Katz
 
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...hospital
 
Nuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptxNuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptxhospital
 
Heart Failure - What to expect from the Investigations?
Heart Failure - What to expect from the Investigations?Heart Failure - What to expect from the Investigations?
Heart Failure - What to expect from the Investigations?Praveen Nagula
 
Final pericardial effusion
Final pericardial effusionFinal pericardial effusion
Final pericardial effusionintelmedico2609
 

Ähnlich wie Dilated cardiomyopathy (20)

MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
MANAGEMENT OF ANTERIOR WALL MI WITH SHOCK IN A NON PCI CENTER
 
Cardiac Amyloidosis Final Presentation.pdf
Cardiac Amyloidosis Final Presentation.pdfCardiac Amyloidosis Final Presentation.pdf
Cardiac Amyloidosis Final Presentation.pdf
 
Multiple myeloma and al amyloidosis
Multiple myeloma and al amyloidosisMultiple myeloma and al amyloidosis
Multiple myeloma and al amyloidosis
 
Restrictive cardiomyopathy
Restrictive cardiomyopathyRestrictive cardiomyopathy
Restrictive cardiomyopathy
 
cardiomyopathy.ppt
cardiomyopathy.pptcardiomyopathy.ppt
cardiomyopathy.ppt
 
cardiomyopathy2 (3).ppt
cardiomyopathy2 (3).pptcardiomyopathy2 (3).ppt
cardiomyopathy2 (3).ppt
 
cardiomyopathy2.ppt
cardiomyopathy2.pptcardiomyopathy2.ppt
cardiomyopathy2.ppt
 
Anaesthesia for ischemic heart disease
Anaesthesia for ischemic heart diseaseAnaesthesia for ischemic heart disease
Anaesthesia for ischemic heart disease
 
Critical limb ischemia. povd . dr mnr
Critical  limb ischemia. povd . dr mnrCritical  limb ischemia. povd . dr mnr
Critical limb ischemia. povd . dr mnr
 
Cardiogenic shock and IABP.pptx
Cardiogenic shock and IABP.pptxCardiogenic shock and IABP.pptx
Cardiogenic shock and IABP.pptx
 
Coronary Artery Aneurysms and Ectasia
Coronary Artery Aneurysms and Ectasia Coronary Artery Aneurysms and Ectasia
Coronary Artery Aneurysms and Ectasia
 
heart failure.pdf
heart failure.pdfheart failure.pdf
heart failure.pdf
 
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
Radionuclide Imaging of Cardiac Amyloidosis and SarcoidosisFELLOWS LECTUREupd...
 
Scd
Scd Scd
Scd
 
Nuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptxNuclear cases Saturday 2023.pptx
Nuclear cases Saturday 2023.pptx
 
Heart Failure
Heart FailureHeart Failure
Heart Failure
 
Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Heart Failure - What to expect from the Investigations?
Heart Failure - What to expect from the Investigations?Heart Failure - What to expect from the Investigations?
Heart Failure - What to expect from the Investigations?
 
Final pericardial effusion
Final pericardial effusionFinal pericardial effusion
Final pericardial effusion
 
IHD.pptx
IHD.pptxIHD.pptx
IHD.pptx
 

Kürzlich hochgeladen

ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 

Kürzlich hochgeladen (20)

ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 

Dilated cardiomyopathy

  • 2. Introduction • Definition: – Dilated left ventricle with systolic dysfunction – not caused by Ischaemic or valvular heart disease – Cardiac dilatation with systolic dysfunction
  • 3. Learning objectives • Epidemiology • Etiology • Pathology • Genetics • Clinical features • Natural history • Diagnosis • Management
  • 4. IDIOPATHIC DILATED CARDIOMYPATHY EPIDEMIOLOGY • ANNUAL INCIDENCE 5-8/100,000 • PREVELANCE 36/ 100,000 • INCREASED RISK ASSOCIATED WITH: – MALE GENDER – BLACK RACE – HYPERTENSION – CHRONIC BETA-AGONIST USE
  • 8. Causes • Ischemic: = 50% atherosclerosis, Kawasaki disease, anomalous origin of left coronary artery • Idiopathic = 45% • Hereditary: = 25 – 35% autosomal dominant, autosomal recessive, X-linked, mitochondrial • Acute and chronic myocarditis: coxsackievirus, HIV adenovirus, • Autoimmune diseases • Chronic tachycardia
  • 9. • Drugs: alcohol, sympathomimetics, anthracyclines • End-stage hypertrophic cardiomyopathy • Endocrine: growth hormone deficiency, hyperthyroidism, hypothyroidism, hypocalcemia, diabetes mellitus, pheochromocytoma • Inborn errors of metabolism • Muscular dystrophies • Nutritional deficiency: selenium, carnitine, thiamine • Peripartum • Structural heart disease • Systemic hypertension • Toxins: cobalt, lead
  • 10. Pathology • Cardiac dilatation – ? Adaptive – due to increased loading conditions – Idiopathic DCM – maladaptive.. • Myocellular hypertrophy and cell death – Cardiac hypertrophy – adaptive response increase in collagen content preserves myocardial performance – Cumulative loss of myofibrils and cardiac myocytes apoptosis, cellular necrosis decrease in the wall thickness
  • 11. • Extracellular matrix remodeling – Cardiac fibroblast proliferate – Mechanically stable cross linked collagen is degraded by metalloproteinases – Excess of poorly cross-linked collagen is deposited into interstitium – Increase myocardial mass, intersitial fibrosis, ventricular dilatation
  • 16. MOLECULAR DEFECTS IN DILATED CARDIOMYOPATHY Fatkin D, et al. NEJM 1999;341 GENES Lamin A/C δ-sarcoglycan Dystrophin Desmin Vinculin Titin Troponin-T α-tropomyosin ß-myosin heavy chain Actin Mitochondrial DNA mutations
  • 19. FAMILIAL DILATED CARDIOMYOPATHY COMMON ASSOCIATED ABNORMALITIES • Conduction system disease • Skeletal muscle myopathy or muscular dystrophy • autosomal dominant inheritance pattern is most common • Recessive , X-linked, mitochondrial • Extracardiac manifestations: – Sensorineural hearing loss – Neutropenia
  • 21. INCIDENCE OF BIOPSY-PROVEN MYOCARDITIS IN PATIENTS WITH DILATED CARDIOMYOPATHY Series Year Patients Positive Biopsy Kunkel et al 1978 66 6% Mason et al 1980 400 3% Noda 1980 52 0.5% Baandrup et al 1981 132 1% O’Connell et al 1981 68 7% Nippoldt et al 1982 170 5% Fenoglio et al 1983 135 25% Unverferth et al 1983 59 6% Parillo et al 1984 74 26% Zee-Cheng et al 1984 35 63% Daly et al 1984 69 17% Bolte et al 1984 91 20% Hosenpud et al 1985 38 16% Mason et al 1995 2233 10% McCarthy et al 1997 1757 14% TOTAL 5379 11.5%
  • 22. Clinical features • Heart failure – congestion : edema, orthopnea, paroxysmal nocturnal dyspnea – reduced cardiac output : fatigue, dyspnea on exertion • Arrhythmias and/or conduction system disease • Thromboembolic disease (from left ventricular mural thrombus)- stroke
  • 23. • Heart failure symptoms 75%-85% • Anginal chest pain 8%-20% • Emboli (systemic or pulmonary) 1%-4% • Syncope <1% • Sudden cardiac death <1%
  • 25. DILATED CARDIOMYOPATHY ELECTROCARDIOGRAPHIC FINDINGS Disease Etiology Pathologic Q-waves Ischemic cardiomyopathy 10/12 (83%)* (n=15) Idiopathic cardiomyopathy 2/21 (10%)+ # (n=21) *LBBB (n=2); paced rhythm (n=1) + LVH (n=10); IVCD (n=3) # P < 0.003 Feld H, et al. Am J Med 1993;94:547-8
  • 31. SEGMENTAL WALL MOTION ABNORMALITIES IN DILATED CARDIOMYOPATHY • Regional wall motion abnormalities observed in at least 50% of patients with non-ischemic causes of dilated cardiomyopathy • Most frequent wall motion abnormalities: – anterior wall & apex • Posterior and lateral walls most likely to be preserved • Type of abnormality: – hypokinesis (83%) – akinesis (11%) – dyskinesis (6%) • Heterogeneity in regional oxidative metabolism using C- 11 acetate clearance has been demonstrated in DCM AJC 1990;65:364-70; Arch Int Med 1992;152:769-72; JACC 1995;25:1258-62
  • 32. MRI • black blood images: enlarged cardiac chambers and thin myocardial walls • Cine images: show LV hypokinesia, increased volumes, (end-diastolic volumes that constitute a dilated CMP: > 140 mL for the LV and > 150 mL for the RV • Phase-contrast sequences: impaired diastolic function. transvalvular flow may be characterized by a restrictive pattern • Late gadolinium-enhancement
  • 37. Differentiation of ischaemic from non-ischaemic DCM
  • 38. ACC/AHA HEART FAILURE EVALUATION GUIDELINES CLASS I & II RECOMMENDATIONS • Laboratory Studies – Blood count, urinalysis, electrolytes, renal function, glucose, LFTs (class I; level C) – Thyroid stimulating hormone (class I; level C) – Fe/TIBC, ferritin (class IIa, level C) – Urinary screening for hemochromatosis (class IIa; level C) – Measurement of ANA, rheumatoid factor, urinary VMA and metanepherines in selected patients (class IIa; level C) – HIV testing (class IIb; level C) • Electrocardiogram (class I; level C) • Chest x-ray (class I; level C) • Echocardiogram/Doppler or radioventriculogram (class I;level C) -Adapted from Hunt SA et al. Circulation 2001;104:2996-3007
  • 39. Genetic test • Genetic Cardiomyopathy dilated panel Next Generation Sequencing Panel: • ABCC9, ACTC1, ACTN2, BAG3, CSRP3, DES, DMD, DSG2, EYA4, FKTN, GATAD1, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, NEXN, PLN, PSEN1, MT-ND1, MT-ND5, MT-ND6, MT-TD, MT-TH, MT-TI, MT-TK, MT-TL1, MT-TL2, MT-TM, MT-TQ, MT-TS1, MT-TS2, PSEN2, RBM20, SCN5A, SDHA, SGCD, TAZ, TCAP, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR, VCL DNA Test
  • 41. IDIOPATHIC DILATED CARDIOMYOPATHY NATURAL HISTORY Dec GW, Fuster V. NEJM 1994;331:1564-75
  • 42. Transplant free survival in acute DCM
  • 43. SPONTANEOUS IMPROVEMENT IN ACUTE DILATED CARDIOMYOPATHY UNIVARIATE PREDICTORS OF IMPROVEMENT short duration of symptoms higher cardiac output lower NYHA functional classification smaller LV end-diastolic dimension lower filling pressures higher serum sodium concentration STEPWISE REGRESSION MODEL short duration of symptoms higher serum sodium concentration lower right atrial pressure lower pulmonary capillary wedge pressure -Steimle AE, et al. JACC 1994;23:553-9
  • 44. CHANGE IN LVEF BY LVEDD: IMAC Trial 0.32 0.56 0.22 0.26 0.39 0.12 0.20 0.29 0.09 0 0.2 0.4 0.6 Baseline LVEF 6 months LVEF 12 months LVEF < or = 6.0 >6 to 7.0 > 7.0 LVEDD (cm) LVEF McNamara D, et al. AHA, 2001 N=82
  • 45. IDCM:PROGNOSTIC FEATURES • VENTRICULOGRAPHIC FINDINGS – Degree of impairment in LVEF – Extent of left ventricular enlargement – Coexistent right ventricular dysfunction – Ventricular mass/volume ratio – Global wall motion abnormalities – Left ventricular sphericity • CLINICAL FINDINGS – Favorable prognosis: NYHA < IV, younger age, female sex – Poor prognosis: Syncope, persistent S3 gallop, right- sided heart failure, AV or bundle branch block, hyponatremia, troponin elevation, increased BNP, maximum oxygen uptake < 12 ml/kg/min
  • 46. OUTCOME IN IDIOPATHIC DILATED CARDIOMYOPATHY PREDICTIVE VALUE OF TROPONIN T Months Event-FreeRate(%) Sato Y et al. Circulation 2001;103:372 Grp 1: TnT < 0.02 ng/mL during follow- up period Grp 2: TnT > 0.02 ng/mL initially but fell to < 0.02 ng/mL during follow-up Grp 3: TnT > 0.02 ng/mL throughout follow-up period N=33 N=10 N=17
  • 47. MYOCARDIAL CONTRACTILE RESERVE PREDICTS IMPROVEMENT IN DILATED CARDIOMYOPATHY Naqvi TS et al. J Am Coll Cardiol 1999;34:1537-44
  • 49. 668N = Fas gene expression HighModerateLow ChangeinEFat12months(%) 50.0 40.0 30.0 20.0 10.0 0.0 -10.0 -20.0 668N = Fas gene expression HighModerateLow 40.0 30.0 20.0 10.0 0.0 -10.0 Fas Expression and LV Recovery p=0.002 p=0.006 Six months Twelve months Sheppard, AHA 2003 IMAC TRIAL RESULT:APOPTOSIS AND RECOVERY OF VENTRICULAR FUNCTION
  • 50. Expression of TNF-alpha and FasL did not predict the recovery Sheppard, AHA 2003 TNFR1 Expression and LV Recovery Six months Twelve months
  • 51. NONINVASIVE ASSESSMENT OF CORONARY ARTERY DISEASE IN NEW ONSET DILATED CARDIOMYOPATHY • Retrospective studies have shown up to 94% of patients with idiopathic dilated cardiomyopathy will have myocardial perfusion defects – Reversible defect(s): 60% – Fixed defect(s): 15% – Reversible+ fixed defect(s): 25% • Global myocardial blood flow reserve (dipyridamole- induced) is diminished in DCM patients compared to controls using PET imaging • Low myocardial blood flow reserve correlates with high left ventricular wall stress and anaerobic metabolism Ann Inter Med 1992;152:679-72; JACC 2000;35:19-28.
  • 52. INDICATIONS FOR CORONARY ANGIOGRAPHY IN NEW ONSET CARDIOMYOPATHY ACC/AHA CONSENSUS GUIDELINES (2001) • Patients with Known Coronary Artery Disease/Angina Pectoris – Revascularization recommended in vast majority of such individuals with multivessel disease. Little role for non-invasive testing. – Coronary angiography considered Class I Recommendation (Level of evidence: B) • Patients with Known Coronary Artery Disease Who Lack Angina – No controlled trials have examined whether coronary revascularization can improve outcomes in this population – Many centers first evaluate patient for myocardial hibernation – Coronary angiography considered Class IIa Recommendation (Level of Evidence:C) • Patients with or without Chest Pain in Whom Coronary Artery Disease has Not Been Evaluated – Approximately 35% of patients with IDCM will report angina-like pain – Coronary angiography should be considered Class IIa recommendation (Level of Evidence: C) Hunt SA,et al. Circulation 2001;104:2996
  • 54. INDICATIONS FOR ENDOMYOCARDIAL BIOPSY • Acute dilated cardiomyopathy with refractory heart failure symptoms • Rapidly progressive ventricular dysfunction in an unexplained cardiomyopathy of recent onset • New onset cardiomyopathy with recurrent ventricular tachycardia or high grade heart block • Heart failure in the setting of fever, rash, and peripheral eosinophilia • Dilated cardiomyopathy in setting of systemic diseases known to affect the myocardium (systemic lupus erythematosus, polymyositis, sarcoidosis) Wu LA, et al. Mayo Clin Proc 2001;76:1030-8
  • 55. DILATED CARDIOMYOPATHY PROVEN THERAPEUTIC OPTIONS TREATMENT INDICATIONS ACE Inhibitors Symptomatic heart failure and asymptomatic LV dysfunction ARBs ACE intolerance Hydralazine- nitrates ACE intolerance Diuretics Volume overload Potassium/Magnesium Diuretic-induced depletion Beta-blockers Symptomatic heart failure in addition to ACE inhibitor Digoxin Persistent heart failure despite diuretics, ACE inhibitor Warfarin Chronic or paroxysmal atrial fibrillation LV thrombus or prior embolic event ICD Cardiac arrest; uncontrolled VT
  • 59. Role of CRT • Survival estimates at 4 years were 55% for ICM and 77% for DCM groups (P<.001), respectively, whereas no significant difference in the incidence of appropriate/inappropriate ICD shocks was observed • Conclusion: In response to CRT and in contrast to ICM, DCM patients experienced greater improvement in left ventricular systolic function and reverse remodeling while also sustaining a greater survival benefit. • Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy Christopher J et al, Heart rhythm, March 2011 Volume 8, Issue 3, Pages 377–382. et al
  • 61. DCM with atrial fibrillation Rate control Rhythm control
  • 62. Alcoholic cardiomypathy • Diagnosis of exclusion • 3.8 – 43 % cases with IDCM • Ethanol consumption > 80 gm/day for male and > 40 gm/ day for female for a period of > 5 years • Absteinance from alcohol after the diagnosis may improve the LVEF.
  • 63. Peripartum cardiomyopathy • definition --- four criteria: three clinical and one echocardiographic – 1. Development of heart failure during last trimester of pregnancy or first six months post partum. 2. Absence of any identifiable cause for cardiac failure. 3. Absence of any recognizable heart disease prior to last trimester of pregnancy. 4. Echocardiographic criteria- Demonstrable echocardiographic proof of left ventricular systolic dysfunction. Ejection fraction less than 45%, left ventricular fractional shortening less than 30% or left ventricular end- diastolic dimension >2.7cm/m square of body surface area.
  • 64. Novel surgical options • Mitral valve repair • Surgical ventricular reconstruction • Surgical attempts to regenerate lost or damaged myocardium with transplanted stem cells.
  • 66. • In refrctory cases – • LVAD • Heart transplatation
  • 67. Summary • DCM – important cause of morbidity and mortality • Ischaemic CMP and Familial DCM – major causes of DCM: role of CAG and genetic counselling • Advancement in immunoabsorption and immunosuppression therapy for myocarditis has improved the survival in recent years. • further studies are needed to fill the lacuna in our knowledge about DCM